Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer

Hashemi-Meshkini, Amir; Keshavarz, Khosro; Gharibnaseri, Zahra; Kheirandish, Mehrnaz; Kebriaeezadeh, Abbas; Nikfar, Shekoufeh; Abdollahi, Mohammad

doi:10.5114/aoms.2013.35347

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is currently treated with conservative surgery, adjuvant and/or neoadjuvant chemotherapy, radiotherapy, and hormone therapy, as appropriate. However, there is an elevated rate of patients who relapse with metastatic disease [ 10 – 12 ]. Therefore, we need to develop new treatments aimed at being more effective and selective, and that contribute to improving the prognosis and survival of patients.…”

Section: Introductionmentioning

confidence: 99%

Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

Carrasco¹,

Garrido²,

Álvarez³

et al. 2016

aoms

View full text Add to dashboard Cite

IntroductionRecently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+ breast cancer cells. In this paper, we characterize allografts of ER+ E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease.Material and methodsTwenty female C57BL/6 mice were injected with 106 E0771 cells. Once the tumors reached the appropriate size, the mice were divided into two groups, one control and another treated orally with 15 mg/kg of meroxest. After 20 days, tumor samples were taken for histopathological study and for determination of the expression of the prognostic markers Ki67 and vascular endothelial growth factor (VEGF) by immunofluorescence.ResultsIn sections stained with hematoxylin-eosin, we observed that tumors have a well-defined capsule enclosing E0771 tumor cells. The central area of tumors contains necrotic regions with leukocyte infiltration. Meroxest treatment significantly reduces tumor size (68%, p < 0.05), induces changes in its structure, decreases the degree of leukocyte infiltration, and significantly reduces the expression of Ki67 (33%, p < 0.05) and VEGF (82%, p < 0.05).ConclusionsMeroxest improves the prognosis of mice since it reduces leukocyte infiltration, and decreases the expression of Ki67 and VEGF markers. Consequently, the merosesquiterpene could become a useful antiangiogenic drug in the treatment of breast cancer. These results encourage us to deepen the study of meroxest, in order to find more evidence that supports the convenience of its evaluation in a clinical study or trial.

show abstract

Section: Introductionmentioning

confidence: 99%

Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

Carrasco¹,

Garrido²,

Álvarez³

et al. 2016

aoms

View full text Add to dashboard Cite

show abstract

“…3 Exemestane (EXE), as illustrated in Figure 1a, is an oral aromatase inhibitor that was approved in 1999 by the USFDA for the treatment of estrogen-receptor positive breast cancer in postmenopausal women. 4 However, it is a BCS class IV drug and thus exhibits high first-pass metabolism, low bioavailability, high lipophilicity, and poor solubility, which subsequently results in limited clinical therapeutic efficacy. 5 Moreover, it has been reported to cause a loss in bone density at an accelerated rate, resulting in its demineralization and subsequently leading to fractures and osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Robust RP-HPLC Method for the Simultaneous Analysis of Exemestane and Thymoquinone and Its Application to Lipid-Based Nanoformulations

Gupta,

Sharma,

Gupta

et al. 2024

ACS Omega

View full text Add to dashboard Cite

The present study describes the development and validation of a simple and rapid HPLC method for the simultaneous quantification of exemestane and thymoquinone. The separation of both compounds was performed on a 5 μ C-18 column utilizing phase A as water/methanol (45:5 v/v) and phase B as acetonitrile (50 v/v) (total ratio of A/B = 40:60 v/v) in isocratic elution mode as the mobile phase at a flow rate of 0.8 mL/min. Further, the Box−Behnken design was used for optimizing the analytical method. The proposed method was validated for various parameters, and all parameters were found to be within an acceptable range. The simultaneous detection of both drugs was monitored at 243 nm with a retention time of 5.73 and 6.93 min, respectively. Moreover, the forced degradation studies were conducted under various stress conditions, and the relevance of the validated RP-HPLC method was further explored for the estimation of drugs from lipid-based nanoformulation. Taken together, the study construed the development of an efficient and robust method that could be used for the quantification of these agents in various in vitro as well as in vivo models.

show abstract

“…Breast cancer is known as the most common cancer among women and all ages are susceptible in both developed and developing countries, and also is the most common malignancy in women [2][3][4]. However, most of the mortalities caused by breast cancer (about 88%) occur in developing countries [5]. This, can be justified with the lower levels of awareness and education in such countries.…”

Section: Introductionmentioning

confidence: 99%

“…The risk factors are genetic and epigenetic factors [18], familial history, age, the ages of menopause and menarche, the age of the first pregnancy, geographical and anthropological variations, previous benign disease, radiation, hormone replacement therapies, the oral contraceptives and life style [19]. The treatment of breast cancer could be through hormone-replacement therapy [20], exemestane (in advanced cases, in the early stage of estrogen receptor positive patients, or in postmenopausal women who have already been treated with tamoxifen for 2-3 years) [5], the platinum compounds affecting cell cycle [21], radiation therapy [22] or immunoradiotherapy as a technic based on monoclonal antibodies [23].…”

Section: Introductionmentioning

confidence: 99%

Investigation of breast cancer screening among the women of Khorramabad (west of Iran): A cross-sectional study

Anbari

Ahmadi

Sahraei

et al. 2022

ebph

View full text Add to dashboard Cite

Abstract. Breast cancer is the most common women's cancer that more than 90% of the patients can be treated or even cured through early diagnosis. So we intend to investigate the status of breast cancer screening in Khorramabad, a city in the west of Iran. In the present cross-sectional study, the study population included 457 number of 20 to 65 year old women referring to the health centers of Khorramabad during the second half of 2015 to receive health care services. The sampling method was multistage random-cluster. A multi-part questionnaire were used. Fisher exact test, chi-square and independent t tests were used to analyze the data. The regular self-breast exam (SBE) had been carried out by 12.3% of the women, visiting doctors for regular clinical breast exam (CBE) had been done by 6% of the respondents and regular mammography every one to two years had been performed by 2.4% of the women. A statistically significant relationship was seen between occupation (P = 0.001), regular consumption of contraceptive pills (P = 0.032), history of breastfeeding, history of breast cancer in the first degree relatives (P = 0.001), and a history of cancer in the second degree (P = 0.005) relatives, and the regular SBE. Planning to enhance the women's awareness about breast cancer and the methods of early diagnosis and designing educational programs can be an important step to reduce deaths and disabilities caused by this disease among the women in such deprived cities.

show abstract

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer

Cited by 7 publications

References 21 publications

Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

Development and Validation of a Robust RP-HPLC Method for the Simultaneous Analysis of Exemestane and Thymoquinone and Its Application to Lipid-Based Nanoformulations

Investigation of breast cancer screening among the women of Khorramabad (west of Iran): A cross-sectional study

Contact Info

Product

Resources

About